To receive information from ONCODESIGN PRECISION MEDICINE (OPM) in real time, send a request to [email protected]
Appointment of Florence Dupré as administrator of the Board of Directors
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, publishes the results of its Combined General Meeting which took place on May 30, 2023 at 2:30 p.m. and announces the appointment of Florence Dupré as administrator of its Board of Directors.
Karine Lignel, Deputy Chief Executive Officer and COO, declares: “I am delighted with the way in which OPM’s first Combined General Meeting took place since its IPO in October 2022. It is an important time of the year when the Management, the Board of Directors and our shareholders meet and make decisions that will guide our future development projects. I am also particularly delighted with the arrival of Florence Dupré on our Board of Directors. An experienced manager at the heart of the healthcare ecosystem in France, she represents a real asset for our team and for the Company, particularly in supporting our CSR policy. »
